纖維囊性乳房診斷和治療市場規模 - 按類型和最終用戶 - 區域前景、競爭策略和細分市場預測（～2033年）

Fibrocystic Breasts Diagnostics Treatment Market Size- By Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

出版日期: 2024年06月03日 | 出版商:

SPER Market Research Pvt. Ltd. | 英文 211 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到2033年，全球纖維囊性乳房診斷和治療市場規模將成長至311.7億美元，年複合成長率為8.11%。

全球纖維囊性乳房診斷和治療市場受到了 COVID-19 疫情的重大影響。為了優先考慮 COVID-19 患者並降低感染風險，許多非緊急治療在疫情高峰期被取消或延遲。因此，纖維囊性乳房疾病患者可能會延遲診斷和治療，導致併發症和疾病進展。

本報告調查了全球纖維囊性乳房診斷和治療市場，並提供了市場概況，市場影響因素和市場機會分析，市場規模推移和預測，各種細分及地區/主要國家的詳細分析，競爭形勢，主要企業簡介等彙整資訊。

According to SPER market research, 'Fibrocystic Breasts Diagnostics Treatment Market Size- By Types, By End-Users - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Fibrocystic Breasts Diagnostics Treatment Market is predicted to reach USD 31.17 billion by 2033 with a CAGR of 8.11%.

Breasts feeling lumpy are a symptom of fibrocystic breast disease, a non-cancerous illness also called fibrocystic change or fibrocystic breasts. The breast lumps are caused by fibrocystic changes. These lumps develop from a concentration of fibrous tissue in one area of the breast. Changes in breast tissue brought on by fluctuations in hormone levels produced by the ovaries are the cause of fibrocystic breasts.

The worldwide market for fibrocystic breast diagnosis and therapy has been greatly influenced by the COVID-19 epidemic. Many non-urgent medical treatments were canceled or postponed during the peak of the pandemic in order to prioritize COVID-19 patients and lower the risk of transmission. As a result, people who have fibrocystic breast disorders might have had delays in their diagnosis and course of treatment, which could have resulted in complications or the advancement of their illness.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Types, By End Users

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Argon Medical Devices, Becton,Dickson and Company, Bayer AG, Boston Scientific Corp, Devicor Medical Products Inc., Johnson & Johnson Pvt. Ltd., Merck, Sanofi, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd.

Global Fibrocystic Breasts Diagnostics Treatment Market Segmentation:

By Types: Based on the Types, Global Fibrocystic Breasts Diagnostics Treatment Market is segmented as; Diagnosis, Mammogram, Breast Biopsy, Treatment, Medications, Acetaminophen. Non-steroidal anti-inflammatory Drugs, Fine-Needle Aspiration, Surgical Excision, Oral Contraceptive

By End-Users: Based on the End-Users, Global Fibrocystic Breasts Diagnostics Treatment Market is segmented as; Hospitals, Clinics, Diagnostic Centers, Speciality Clinics and Rehab Centers, Research Institutes, Others.)

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Fibrocystic Breasts Diagnostics Treatment Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Fibrocystic Breasts Diagnostics Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Fibrocystic Breasts Diagnostics Treatment Market

7. Global Fibrocystic Breasts Diagnostics Treatment Market, By Type (USD Million) 2020-2033

7.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By Type, 2020-2026
7.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By Type, 2027-2033
7.3. Diagnosis
7.4. Mammogram
7.5. Breast Biopsy
7.6. Treatment
7.7. Medications
7.8. Acetaminophen
7.9. Non-steroidal Inflammatory Drugs
7.10. Fine-needle Aspirations
7.11. Surgical Excision
7.12. Oral Contraceptives

8. Global Fibrocystic Breasts Diagnostics Treatment Market, By End-Users (USD Million)2020-2033

8.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By End Users, 2020-2026
8.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By End Users, 2027-2033
8.3. Hospitals
8.4. Clinics
8.5. Diagnostic Centers
8.6. Speciality Clinics and Rehab Centers
8.7. Research Institutes
8.8. Others

9. Global Fibrocystic Breasts Diagnostics Treatment Market Forecast, 2020-2033 (USD Million)

9.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share

10. Global Fibrocystic Breasts Diagnostics Treatment Market, By Region, 2020-2033 (USD Million)

10.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share By Region (2020-2026)
10.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share By Region (2027-2033)
10.3. Asia-Pacific
- 10.3.1. Australia
- 10.3.2. China
- 10.3.3. India
- 10.3.4. Japan
- 10.3.5. South Korea
- 10.3.6. Rest of Asia-Pacific
10.4. Europe
- 10.4.1. France
- 10.4.2. Germany
- 10.4.3. Italy
- 10.4.4. Spain
- 10.4.5. United Kingdom
- 10.4.6. Rest of Europe
10.5. Middle East and Africa
- 10.5.1. Kingdom of Saudi Arabia
- 10.5.2. United Arab Emirates
- 10.5.3. Qatar
- 10.5.4. South Africa
- 10.5.5. Egypt
- 10.5.6. Morocco
- 10.5.7. Nigeria
- 10.5.8. Rest of Middle East & Africa
10.6. North America
- 10.6.1. Canada
- 10.6.2. Mexico
- 10.6.3. United States
10.7. Latin America
- 10.7.1. Argentina
- 10.7.2. Brazil
- 10.7.3. Rest of Latin America

11. Company Profile

11.1. Argon Medical Devices
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. Becton, Dickinson and Company
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. Bayer AG
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. Boston Scientific Corp.
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. Devicor Medical Products Inc.
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. Johnson & Johnson Pvt. Ltd.
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. Merck
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. Sanofi
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. Sun Pharmaceutical Industries
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
11.10. Teva Pharmaceutical Industries Ltd.
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
11.11. Others